Evidence map›Paper›PMID 38264755›Full record

ArticleFrontiers in oncology2023

A cohort profile of the Graham Roberts study cohort.

Beth Russell, Poppy Leech, Harriet Wylie, Charlotte Louise Moss, Anna Haire, Deborah Enting, Suzanne Amery, Kathryn Chatterton, Muhammad Shamim Khan, Ramesh Thurairaja and 10 more

Abstract read
In one paragraph

Article in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Beth RussellTranslational Oncology and Urology Research, School of Cancer and Pharmaceutical Sciences, King's College London, London, United Kingdom.
Poppy LeechTranslational Oncology and Urology Research, School of Cancer and Pharmaceutical Sciences, King's College London, London, United Kingdom.
Harriet WylieTranslational Oncology and Urology Research, School of Cancer and Pharmaceutical Sciences, King's College London, London, United Kingdom.
Charlotte Louise MossTranslational Oncology and Urology Research, School of Cancer and Pharmaceutical Sciences, King's College London, London, United Kingdom.
Anna HaireTranslational Oncology and Urology Research, School of Cancer and Pharmaceutical Sciences, King's College London, London, United Kingdom.
Deborah EntingUrology, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom.
Suzanne AmeryUrology, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom.
Kathryn ChattertonUrology, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom.
Muhammad Shamim KhanUrology, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom.
Ramesh ThurairajaUrology, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom.
Rajesh NairUrology, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom.
Sachin MaldeUrology, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom.
Kate SmithUrology, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom.
Cheryl GillettKing's Health Partners Cancer Biobank, King's College London, London, United Kingdom.
Debra JosephsUrology, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom.
Elias PintusUrology, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom.
Sarah RudmanUrology, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom.
Simon HughesUrology, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom.
Clare ReltonWolfson Institute of Population Health, Queen Mary University of London, London Sheffield, United Kingdom.
Mieke Van HemelrijckTranslational Oncology and Urology Research, School of Cancer and Pharmaceutical Sciences, King's College London, London, United Kingdom.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: The Graham Roberts Study was initiated in 2018 and is the first Trials Within Cohorts (TwiCs) study for bladder cancer. Its purpose is to provide an infrastructure for answering a breadth of research questions, including clinical, mechanistic, and supportive care centred questions for bladder cancer patients. Participants: All consented patients are those aged 18 or older, able to provide signed informedconsent and have a diagnosis of new or recurrent bladder cancer. All patients are required to have completed a series of baseline questionnaires. The questionnaires are then sent out every 12 months and include information on demographics and medical history as well as questionnaires to collect information on quality of life, fatigue, depression, overall health, physical activity, and dietary habits. Clinical information such as tumor stage, grade and treatment has also been extracted for each patient. Findings to date: To date, a total of 125 bladder cancer patients have been consented onto the study with 106 filling in the baseline questionnaire. The cohort is made up of 75% newly diagnosed bladder cancer patients and 66% non-muscle invasive bladder cancer cases. At present, there is 1-year follow-up information for 70 patients, 2-year follow-up for 57 patients, 3-year follow-up for 47 patients and 4-year follow-up for 19 patients. Future plans: We plan to continue recruiting further patients into the cohort study. Using the data collected within the study, we hope to carry out independent research studies with a focus on quality of life. We are also committed to utilizing the Roberts Study Cohort to set up and commence an intervention. The future studies and trials carried out using the Roberts Cohort have the potential to identify and develop interventions that could improve the prevention, diagnosis, and treatment of bladder cancer.

Indexed as

cohort profilemuscle invasive bladder cancer (MIBC)non-muscle invasive bladder cancer (NMIBC)questionnairestrials within cohorts

Identifiers

PMID38264755
PMCPMC10803459

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.